SAKINA has initiated a partnership with PeakLogic to investigate advanced brain stimulation research, the Emirates News Agency reported on September 10. The UAE-based health technology firm aims to adapt personalized repetitive transcranial magnetic stimulation protocols that use electroencephalogram data to tailor treatments for individual patients. This move aligns with broader efforts to address neurological and psychiatric conditions through non-invasive methods rather than relying solely on pharmacological interventions. PeakLogic’s technology focuses on adjusting brain frequencies based on spectral EEG analyses to target specific disorders.
A retrospective review published by PeakLogic researchers in the journal Brain Stimulation found that 84 percent of patients with post-traumatic stress disorder responded to personalized repetitive transcranial magnetic stimulation, with a mean reduction of 23 points on the PCL-5 symptom scale. The company’s published data also indicate that EEG power spectrum peaks typically shifted toward each patient’s personal alpha peak frequency following treatment courses. Such findings stem from clinical observations involving military veterans and other cohorts experiencing trauma-related symptoms. PeakLogic has documented similar positive outcomes in pilot studies addressing autism spectrum disorder and concussion symptoms.
The global brain health devices market reached $11.9 billion in 2025 and is projected to expand to $12.79 billion in 2026, according to figures from The Business Research Company. Growth in the sector is driven by rising prevalence of neurological disorders alongside technological advances in monitoring and stimulation platforms. Non-invasive approaches like transcranial magnetic stimulation have gained traction as regulators approve their use for conditions including depression, migraine and tinnitus. Industry assessments anticipate continued expansion through 2030 as wearable and home-based solutions enter the market.
SAKINA’s exploration of these technologies will focus on regional adaptation and potential clinical applications suitable for Middle Eastern patient populations, the company indicated in statements carried by WAM. Collaboration with PeakLogic includes knowledge transfer on EEG-guided targeting and protocol customization to ensure treatments match individual brain activity patterns. The initiative builds on PeakLogic’s existing patents for systems that determine personalized resonant frequencies and minimum neuronal activation thresholds before delivering magnetic pulses. Early integration efforts will emphasize safety protocols and data collection to support future regulatory submissions.
PeakLogic has secured multiple patents assigned to the company for transcranial magnetic stimulation systems that process EEG signals in real time to generate customized treatment parameters, according to records from the United States Patent and Trademark Office. These include methods for identifying optimal stimulation locations near white matter pathways that connect to memory and other functional networks. Clinical data distributed by the firm show reductions in anxiety, depression and neurobehavioral symptoms when personalized stimulation is combined with other modalities such as transcranial photobiomodulation. The partnership with SAKINA marks an expansion of PeakLogic’s technology into new geographic markets.
Further details on the collaboration’s timeline and specific research protocols remain under development as the two organizations establish joint working groups, WAM noted in its coverage. SAKINA brings local regulatory expertise and access to regional healthcare infrastructure that could accelerate implementation studies. PeakLogic’s prior work with military and civilian populations provides a foundation of evidence that the partners plan to build upon through targeted trials. The announcement reflects increasing interest in neuromodulation across the Gulf region as part of wider health technology investments.
